Patents by Inventor Michael C. Jensen

Michael C. Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240131072
    Abstract: Activity-inducible fusion proteins whose activity is post-translationally regulated utilizing a hsp90 binding domain and a drug molecule are described. In the absence of the drug molecule, the activity-inducible fusion proteins are inactivated but can be activated by a relevant physiological parameter in the presence of the drug molecule. Examples of the activity-inducible fusion proteins include chimeric antigen receptors (CAR) wherein the relevant physiological parameter is antigen binding.
    Type: Application
    Filed: February 11, 2022
    Publication date: April 25, 2024
    Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    Inventors: Ryan Koning, Adam Johnson, Chris Saxby, Michael C. Jensen, Ian Blumenthal, Aquene Reid
  • Patent number: 11944648
    Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
    Type: Grant
    Filed: August 25, 2023
    Date of Patent: April 2, 2024
    Assignees: The Regents of the University of California, Seattle Children's Hospital
    Inventors: Yvonne Y. Chen, Eugenia Zah, Michael C. Jensen
  • Publication number: 20240093178
    Abstract: Aspects of the invention described herein relate to methods of making and using inducible promoters for transgene expression. The inducible promoters are derived from the NFAT-RE inducible system and are used to improve or enhance T cell survival and proliferation.
    Type: Application
    Filed: November 27, 2023
    Publication date: March 21, 2024
    Applicant: SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE)
    Inventors: Jia Wei, Michael C. Jensen
  • Publication number: 20240091256
    Abstract: Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (TME) and methods of modifying a tumor microenvironment (TME). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces T-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred NK or T cells and/or induces production of an interleukin, an interferon, a PD-1 checkpoint binding protein, HMGB1, MyD88, a cytokine or a chemokine. Methods of modulating the suppression of the immune response in a tumor microenvironment, minimizing the proliferation of tumor and suppressive cells, and increasing the efficiency of an anti-cancer therapy, anti-infection therapy, antibacterial therapy, anti-viral therapy, or anti-tumoral therapy are also provided.
    Type: Application
    Filed: October 17, 2023
    Publication date: March 21, 2024
    Inventors: Courtney Crane, Michael C. Jensen, Kara White Moyes, Nicole Lieberman
  • Publication number: 20240075069
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Application
    Filed: August 31, 2023
    Publication date: March 7, 2024
    Inventors: Philip Stewart LOW, Haiyan CHU, Yingjuan June LU, Christopher Paul LEAMON, Leroy W. WHEELER, II, Michael C. JENSEN, James MATTHAEI
  • Publication number: 20240043544
    Abstract: Disclosed herein is a polynucleotide comprising a human codon-optimized sequence encoding a polypeptide comprising EGFR806CAR. The codon-optimized sequence may be incorporated into a construct comprising an optimal-functioning promoter, spacer, intracellular signaling domain, transmembrane domain, selection marker, at least one self-cleaving peptides, and EFGRt, in order to optimize expression. This sequence may then be expressed in cells, such as T cells, for the treatment or inhibition of a cancer, such as glioblastoma, liquid tumors, or solid tumors.
    Type: Application
    Filed: December 3, 2021
    Publication date: February 8, 2024
    Inventors: Michael C. Jensen, Jia Wei
  • Publication number: 20240024359
    Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 25, 2024
    Inventors: Yvonne Y. Chen, Eugenia Zah, Michael C. Jensen
  • Patent number: 11851649
    Abstract: Aspects of the invention described herein relate to methods of making and using inducible promoters for transgene expression. The inducible promoters are derived from the NFAT-RE inducible system and are used to improve or enhance T cell survival and proliferation.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: December 26, 2023
    Assignee: Seattle Children's Hospital
    Inventors: Jia Wei, Michael C. Jensen
  • Patent number: 11826384
    Abstract: Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (TME) and methods of modifying a tumor microenvironment (TME). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces T-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred NK or T cells and/or induces production of an interleukin, an interferon, a PD-1 checkpoint binding protein, HMGB1, MyD88, a cytokine or a chemokine. Methods of modulating the suppression of the immune response in a tumor microenvironment, minimizing the proliferation of tumor and suppressive cells, and increasing the efficiency of an anti-cancer therapy, anti-infection therapy, antibacterial therapy, anti-viral therapy, or anti-tumoral therapy are also provided.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: November 28, 2023
    Assignee: Seattle Children's Hospital
    Inventors: Courtney Crane, Michael C. Jensen, Kara White Moyes, Nicole Lieberman
  • Publication number: 20230374104
    Abstract: Some embodiments of the methods and compositions provided herein relate to chimeric proteins comprising a programmed cell death protein 1 (PD 1) extracellular domain and an intracellular immunostimulatory domain. Some embodiments include a cell containing a PD 1 chimeric polypeptide and a chimeric antigen receptor (CAR). In some embodiments, the CAR comprises a ligand binding domain capable of specifically binding to a target antigen on a solid tumor. More embodiments relate to therapies to treat, inhibit or ameliorate certain disorders, such as a cancer, such as a solid tumor.
    Type: Application
    Filed: October 7, 2021
    Publication date: November 23, 2023
    Inventors: Michael C. Jensen, Adam Johnson, James Rosser
  • Publication number: 20230322925
    Abstract: Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
    Type: Application
    Filed: March 24, 2023
    Publication date: October 12, 2023
    Inventors: Michael C. Jensen, James Matthaei
  • Publication number: 20230322937
    Abstract: Provided are methods for preventing or ameliorating toxicity caused by or due to a therapy, such as an immunotherapy or a cell therapy, by pre-emptive or early administration toxicity-targeting agent(s). In some embodiments, the therapy is a cell therapy in which the cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the methods, including the timing of the administration of the agents or treatments for toxicity, provide various advantages, such as lower toxicity while maintaining persistence and efficacy of the administered cells.
    Type: Application
    Filed: June 6, 2023
    Publication date: October 12, 2023
    Inventors: Michael C. Jensen, Rebecca Gardner
  • Patent number: 11779602
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: October 10, 2023
    Assignees: Endocyte, Inc., Purdue Research Foundation, Seattle Children's Hospital
    Inventors: Philip Stewart Low, Haiyan Chu, Yingjuan June Lu, Christopher Paul Leamon, Leroy W. Wheeler, II, Michael C. Jensen, James Matthaei
  • Publication number: 20230303643
    Abstract: Some embodiments of the methods and compositions provided herein relate to chimeric proteins comprising a T cell factor 1 (TCF1) domain and a ?-catenin transactivation domain. In some embodiments, populations of cells containing such chimeric proteins have an increased level of memory T cell associated markers and activities compared to populations lacking the chimeric proteins. Some embodiments include populations of cells comprising the chimeric proteins and chimeric antigen receptors and uses thereof.
    Type: Application
    Filed: August 18, 2021
    Publication date: September 28, 2023
    Inventors: Christopher P. Saxby, Michael C. Jensen
  • Patent number: 11760804
    Abstract: Provided are methods for preventing or ameliorating toxicity caused by or due to a therapy, such as an immunotherapy or a cell therapy, by pre-emptive or early administration toxicity-targeting agent(s). In some embodiments, the therapy is a cell therapy in which the cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the methods, including the timing of the administration of the agents or treatments for toxicity, provide various advantages, such as lower toxicity while maintaining persistence and efficacy of the administered cells.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: September 19, 2023
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, Rebecca Gardner
  • Publication number: 20230242936
    Abstract: Some embodiments of the methods and compositions provided herein relate to systems comprising a promoter operably linked to a nucleic acid encoding a receptor, and an inducible promoter operably linked to a nucleic acid encoding a payload. In some embodiments, transcription from the inducible promoter is induced by activation of the receptor. In some embodiments, transcription from the inducible promoter is further modulated by inhibiting a signal between the activated receptor and the inducible promoter.
    Type: Application
    Filed: May 12, 2021
    Publication date: August 3, 2023
    Inventors: Michael C. Jensen, Jia Wei
  • Publication number: 20230212257
    Abstract: Embodiments of the methods and compositions provided herein relate to anti-CD171 chimeric antigen receptors (CARs). Some embodiments relate to anti-CD171 CARs having long extracellular polypeptide spacers. Some embodiments relate to cells containing such anti-CD171 CARs having increased persistence and activity at a lower dose in a subject compared to cells containing anti-CD171 CARs comprising shorter polypeptide spacers.
    Type: Application
    Filed: June 7, 2021
    Publication date: July 6, 2023
    Inventors: Michael C. Jensen, Adam Johnson
  • Publication number: 20230212298
    Abstract: Provided are methods for preventing or ameliorating toxicity caused by or due to a therapy, such as an immunotherapy or a cell therapy, by pre-emptive or early administration toxicity-targeting agent(s). In some embodiments, the therapy is a cell therapy in which the cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the methods, including the timing of the administration of the agents or treatments for toxicity, provide various advantages, such as lower toxicity while maintaining persistence and efficacy of the administered cells.
    Type: Application
    Filed: December 5, 2022
    Publication date: July 6, 2023
    Inventors: Michael C. Jensen, Rebecca Gardner
  • Publication number: 20230172981
    Abstract: Some embodiments of the methods and compositions provided herein relate to the use of hapten labeled cells to stimulate chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells can include a CAR that specifically binds to a hapten. Some embodiments relate to the in vivo or in vitro stimulation CAR T cells by hapten labeled cells.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 8, 2023
    Inventors: Michael C. Jensen, James F. Matthaei
  • Patent number: 11649288
    Abstract: Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: May 16, 2023
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, James Matthaei